Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
出版年份 2022 全文链接
标题
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-01-19
DOI
10.3389/fphar.2021.807548
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment
- (2021) Chien-Ting Wu et al. Cell Metabolism
- Efficacy and safety of 28‐day treatment with oral insulin ( ORMD ‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial
- (2021) Roy Eldor et al. DIABETES OBESITY & METABOLISM
- Trends in kinase drug discovery: targets, indications and inhibitor design
- (2021) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- The methionine aminopeptidase 2 inhibitor ZGN‐1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo‐controlled trial
- (2020) John M. Wentworth et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study
- (2020) Stefano Del Prato et al. DIABETES OBESITY & METABOLISM
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus
- (2020) Moon-Kyu Lee et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept
- (2020) Christopher A. Lipinski et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Pharmacokinetic and dose‐finding studies of efpeglenatide in patients with type 2 diabetes
- (2020) Kun‐Ho Yoon et al. DIABETES OBESITY & METABOLISM
- Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
- (2020) Konstantinos A. Toulis et al. DRUGS
- Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
- (2020) Angelica Artasensi et al. MOLECULES
- Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
- (2020) Maria Mirabelli et al. International Journal of Environmental Research and Public Health
- Drug Therapy in Obesity: A Review of Current and Emerging Treatments
- (2020) David M. Williams et al. Diabetes Therapy
- Type 1 diabetes onset triggered by COVID-19
- (2020) Lucien Marchand et al. ACTA DIABETOLOGICA
- Prevalence of insulin as a first‐line therapy and associated factors in people with type 2 diabetes in German primary care practices
- (2020) L. Boom et al. DIABETIC MEDICINE
- Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study
- (2020) Carlo Bruno Giorda et al. Diabetes Therapy
- Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
- (2020) Federica Saponaro et al. Frontiers in Medicine
- The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway
- (2020) Shumin Jiang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Soluble ligands as drug targets
- (2020) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors
- (2020) Joseph Lau et al. Pharmaceuticals
- ANGPTL3: a Novel Biomarker and Promising Therapeutic Target
- (2019) Shuang Jiang et al. JOURNAL OF DRUG TARGETING
- 11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study
- (2019) Ravindra Shukla et al. BMC Endocrine Disorders
- AMP-activated protein kinase: the current landscape for drug development
- (2019) Gregory R. Steinberg et al. NATURE REVIEWS DRUG DISCOVERY
- Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
- (2019) Eliza Christopoulou et al. DISEASE MARKERS
- Angiopoietin-like 3 Protein Inhibition
- (2019) William Lang et al. Cardiology in Review
- Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
- (2019) Emily Brown et al. Obesity Reviews
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018
- (2019) Sara Ramzan et al. Primary Care Diabetes
- Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
- (2019) Zahid Ahmad et al. CIRCULATION
- The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
- (2019) David S. Mathiesen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A population‐based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns
- (2019) Matthew H. Secrest et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Thiazolidinediones: the Forgotten Diabetes Medications
- (2019) Harold E. Lebovitz Current Diabetes Reports
- Anti-diabetic compounds from the seeds of Psoralea corylifolia
- (2019) Gaohui Zhu et al. FITOTERAPIA
- Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors
- (2019) Dong Jin Hong et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK
- (2019) Yu Wang et al. Cell Reports
- Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
- (2019) Viswanathan Mohan et al. Diabetes Therapy
- Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
- (2018) Xia Wang et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03)
- (2018) Ritsuko Yamamoto-Honda et al. INTERNAL MEDICINE
- Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061
- (2018) Bryan F. Burkey et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes
- (2018) Marco Bugliani et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Glucagon-like peptide 1 in health and disease
- (2018) Andreas Andersen et al. Nature Reviews Endocrinology
- Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes
- (2018) Santhosh F. Neelamkavil et al. ACS Medicinal Chemistry Letters
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
- (2018) Paranjeet Kaur et al. CURRENT DRUG TARGETS
- Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program
- (2018) Bernhard Kulzer et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway
- (2018) Wei Zhao et al. LIFE SCIENCES
- Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
- (2018) Roger W. Hunter et al. NATURE MEDICINE
- Mechanisms of Insulin Action and Insulin Resistance
- (2018) Max C. Petersen et al. PHYSIOLOGICAL REVIEWS
- Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
- (2018) Samantha Wilkinson et al. BMJ Open
- Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
- (2018) Caroline K. Kramer et al. JACC-Heart Failure
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk
- (2018) Motoaki Sano Journal of Cardiology
- Sulfonyl(thio)urea derivative induction of insulin secretion is mediated by potassium, calcium, and sodium channel signal transduction
- (2018) Paola Miranda Sulis et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Diabesity and antidiabetic drugs
- (2018) Joseph M. Pappachan et al. MOLECULAR ASPECTS OF MEDICINE
- Orphan Drugs and Their Impact on Pharmaceutical Development
- (2018) Misty M. Attwood et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
- (2017) André J. Scheen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
- (2017) Evgenia Gourgari et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Trends in GPCR drug discovery: new agents, targets and indications
- (2017) Alexander S. Hauser et al. NATURE REVIEWS DRUG DISCOVERY
- Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: a nationwide, population-based study
- (2017) Pei-Chen Wu et al. Oncotarget
- Insulin Resistance, Type 1 and Type 2 Diabetes, and Related Complications 2017
- (2017) Joseph Fomusi Ndisang et al. Journal of Diabetes Research
- Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study
- (2017) Peter Eibich et al. Diabetes Therapy
- Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
- (2017) Arun Chaudhury et al. Frontiers in Endocrinology
- Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study
- (2017) Peter Eibich et al. Diabetes Therapy
- Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity
- (2016) Michael Morgen et al. ACS Chemical Biology
- Cerebrovascular Safety of Sulfonylureas: The Role of KATPChannels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes
- (2016) Rui Liu et al. DIABETES
- Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
- (2016) Khalid A. Jadoon et al. DIABETES CARE
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- (2016) Hiroyuki Ito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis
- (2016) Longhao Zhang et al. Scientific Reports
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- State of the art paper Sulfonylureas and their use in clinical practice
- (2015) Daniele Sola et al. Archives of Medical Science
- Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes
- (2015) Dai Lu et al. CELL STRESS & CHAPERONES
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
- (2015) Ulrike Hostalek et al. DRUGS
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
- (2015) Kurt Ritter et al. JOURNAL OF MEDICINAL CHEMISTRY
- DPP4 in diabetes
- (2015) Diana Röhrborn Frontiers in Immunology
- Metformin: From Mechanisms of Action to Therapies
- (2014) Marc Foretz et al. Cell Metabolism
- Managing diabetes with nanomedicine: challenges and opportunities
- (2014) Omid Veiseh et al. NATURE REVIEWS DRUG DISCOVERY
- Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus
- (2014) Tadeusz Kolodka et al. PLoS One
- Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
- (2014) Hye-soon Kim et al. Journal of Diabetes Investigation
- AMPK activation: a therapeutic target for type 2 diabetes?
- (2014) Asish Saha et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
- (2014) Brian Irons et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
- (2014) Amit Joharapurkar et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
- (2013) Mathias Rask-Andersen et al. Annual Review of Pharmacology and Toxicology
- State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
- (2013) Rodolfo Guardado-Mendoza et al. Archives of Medical Science
- The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
- (2013) Hanford Yau et al. Current Diabetes Reports
- GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
- (2013) Sang-Uk Kang DRUG DISCOVERY TODAY
- Safety and Efficacy of the Nonsystemic Chewable Complex Carbohydrate Dietary Supplement PAZ320 on Postprandial Glycemia When Added to Oral Agents or Insulin in Patients with Type 2 Diabetes Mellitus
- (2013) Laura Trask et al. Endocrine Practice
- Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011
- (2013) Takahide Kohro et al. International Heart Journal
- Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
- (2013) Young-Sun Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
- (2013) Franz M. Matschinsky TRENDS IN PHARMACOLOGICAL SCIENCES
- Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
- (2011) H. E. Lebovitz DIABETES CARE
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
- (2011) Tina Ken Schramm et al. EUROPEAN HEART JOURNAL
- TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
- (2011) Shitalkumar Zambad et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes
- (2010) Yi Lin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities
- (2009) William I. Sivitz et al. ANTIOXIDANTS & REDOX SIGNALING
- Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies
- (2008) A. D. Rao et al. DIABETES CARE
- GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity
- (2007) H A Overton et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started